National Multiple Sclerosis Society (NMSS)

Myrobalan Therapeutics is a biotechnology company dedicated to developing oral neurorestorative therapies that target brain dysfunctions and central nervous system (CNS) disorders. The company leverages its deep understanding of neurological processes, including demyelination and neuroinflammation, to identify and develop innovative therapeutic candidates. With a focus on reversing the underlying pathologies of CNS conditions, Myrobalan Therapeutics aims to address significant unmet medical needs. Their dedicated team of scientists employs advanced drug discovery tools to create selective and brain-penetrant therapies, ultimately enabling healthcare professionals to offer new treatment options to a large patient population affected by CNS disorders.

eSupport Health, established in November 2019 as a Delaware Public Benefit Corporation, focuses on enhancing the mental health of individuals living with multiple sclerosis (MS) and other chronic conditions. The company provides professional support groups tailored for those diagnosed with MS, newly diagnosed individuals, and their family members. These groups convene weekly through secure online video sessions, led by experienced coaches who are licensed therapists with expertise in MS. eSupport Health offers the first month of participation free of charge and also hosts free monthly workshops accessible to all registered participants. Through its services, the company aims to deliver practical solutions that foster emotional well-being in a supportive community.

BrainStorm Cell Therapeutics Inc. is a biotechnology company focused on developing and commercializing adult stem cell therapies for neurodegenerative diseases. Their proprietary technology, NurOwn, utilizes a patient's own mesenchymal stem cells, which are engineered to produce neurotrophic factors that promote neuronal survival. The company is actively advancing NurOwn through clinical trials for conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. Currently, NurOwn is in a Phase III clinical trial for ALS and a Phase II trial for MS, with plans for preclinical studies targeting Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. BrainStorm has partnered with Catalent for the manufacturing of NurOwn, ensuring the production of this autologous cellular therapy. Founded in 2000 and headquartered in New York, BrainStorm Cell Therapeutics was previously known as Golden Hand Resources Inc. before rebranding in 2004.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Longevity Biotech, Inc. is a biopharmaceutical company focused on developing innovative therapeutic drug candidates using its proprietary Hybridtide peptide technology. This platform enables the creation of customizable peptides that offer improved stability and absorption, enhancing treatment options for various medical conditions. The company's pipeline includes LBT-3627, a neuroprotective agent aimed at treating disorders such as Parkinson's disease; LBT-6030, a dual agonist targeting glucagon for metabolic conditions; and LBT-5001, a fusion inhibitor. Additionally, Longevity Biotech is conducting clinical studies to identify specific immune and inflammatory markers for the diagnosis of Parkinson's disease. Founded in 2010 and based in Philadelphia, Pennsylvania, Longevity Biotech is committed to advancing drug discovery and development in the biopharmaceutical sector.

NeuroGenesis is a biotechnology company that focuses on developing cell therapies for neurodegenerative diseases. Its primary innovation is the NG CELL™ technology, which uses the patient’s own stem cells to deliver remyelinating and regenerative proteins. This process begins with the collection of bone marrow from the patient, allowing for the neutralization of the stem cell protocol. By maximizing the potential for immunomodulation, neuronal protection, and regeneration, NeuroGenesis aims to enable healthcare professionals to utilize these cells to deliver therapeutic effects directly to affected areas in the brain. The company's approach represents a significant advancement in the treatment of conditions that impact neural health.